A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer
Status:
Terminated
Trial end date:
2018-01-09
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1 study is to determine if AMG 211 given as a continous intravenous
(IV) infusion is safe and tolerable in adult participants that have advanced gastrointestinal
adenocarcinoma. The study will be conducted in multiple sites and test increasing doses of
AMG 211. The safety of participants will be monitored by intensive assessment of vital signs,
electrocardiograms, physical examinations, and laboratory tests. Efficacy will be assessed by
the usual imaging procedures and their interpretation.